This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
-- Sigma-Tau Pharmaceuticals, Inc. Announces Co-Pay Program for Oncaspar® (pegaspargase) --GAITHERSBURG, Md.,
June 27, 2011 /PRNewswire-USNewswire
/ -- Today, Sigma-Tau Pharmaceuticals, Inc. announced a vital new service for people with Acute Lymphoblastic Leukemia (ALL). The Sigma-Tau Outreach Service (S.O.S.) will now refund eligible patients 100 percent of any co-pay associated with their prescription for Oncaspar®. For more information on eligibility criteria, please call 1-800-490-3262, Monday through Friday,
9 a.m. to 5 p.m. ET.
"It is important to Sigma-Tau that families and patients accessing our medicines do not suffer financial distress," said
Gregg Lapointe, Chief Executive Officer, Sigma-Tau Pharmaceuticals, Inc. "This program is designed to ensure that patients and families battling ALL will not be burdened with co-pays tied to Oncaspar®, regardless of income."
The S.O.S. resource provides patients, families and healthcare providers with the following free services:
Reimbursement Support: Trained specialists will help patients understand how to effectively navigate their insurance coverage and address common issues, such as prior authorization or appeals. Specialists also will work to identify additional benefit programs patients might be eligible to join.
Patient Assistance: Sigma-Tau Pharmaceuticals, Inc. will provide eligible patients who cannot pay for Oncaspar® with the treatment at no charge.
Oncaspar® Co-pay Assistance: Eligible patients will receive 100 percent reimbursement for all co-pays associated with the utilization of Oncaspar® with no limitations on family income or financial status.
"Today's insurance programs are complex. The trained specialists available through the S.O.S. service can help people navigate insurance coverage and reimbursement concerns. We're very proud to offer this service, so patients can focus on their treatment," said Lapointe.